M&A: 2017 proves snooze-worthy on the acquisition front
Pharma and biotech takeover activity slumps to a five-year low in 2017.
Asia wins 2017’s mid-cap race
A cooling of the M&A climate allows Asia-based groups to come to the fore.
Back to the future for small caps, but not all benefit
Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.